Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
hospital settings
intravenous infusion medical supervision high-risk individuals outpatient settings in emergency situations patients with confirmed COVID-19 |
| gptkbp:approves |
gptkb:vaccine
November 2020 |
| gptkbp:associated_with |
side effects
|
| gptkbp:available_at |
healthcare providers
|
| gptkbp:available_on |
subcutaneous injection
|
| gptkbp:can_be_combined_with |
other COVID-19 treatments
|
| gptkbp:can_be_used_in |
pediatric patients
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:composed_of |
gptkb:casirivimab
gptkb:imdevimab |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Regen-COV
|
| gptkbp:indication |
high-risk patients
|
| gptkbp:involves |
patient monitoring
|
| gptkbp:is_a |
gptkb:vaccine
substitute for vaccination |
| gptkbp:is_associated_with |
clinical outcomes
|
| gptkbp:is_considered |
therapeutic intervention
a significant advancement in treatment options. an important tool in pandemic management emergency use in outbreaks |
| gptkbp:is_designed_to |
preventive use
|
| gptkbp:is_effective_against |
variants of SARS-Co V-2
|
| gptkbp:is_evaluated_by |
ongoing studies
safety and efficacy placebo long-term effects real-world studies |
| gptkbp:is_part_of |
treatment protocols
treatment regimens COVID-19 response efforts therapeutic strategies for COVID-19 monoclonal antibody treatments |
| gptkbp:is_recommended_by |
health authorities
|
| gptkbp:is_recommended_for |
certain demographics
|
| gptkbp:is_studied_for |
post-exposure prophylaxis
|
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_subject_to |
regulatory oversight
|
| gptkbp:is_used_for |
COVID-19 patients
|
| gptkbp:is_used_in |
clinical practice
|
| gptkbp:marketed_as |
gptkb:REGEN-COV
|
| gptkbp:mechanism_of_action |
neutralizing antibodies
|
| gptkbp:part_of |
COVID-19 treatment guidelines
|
| gptkbp:received_emergency_use_authorization |
gptkb:FDA
|
| gptkbp:requires |
informed consent
|
| gptkbp:requires_prescribing_information |
yes
|
| gptkbp:shown_to_reduce |
hospitalization rates
death rates |
| gptkbp:suitable_for |
mild COVID-19 cases
|
| gptkbp:supports |
immune response
|
| gptkbp:targeted_virus |
gptkb:SARS-Co_V-2
|
| gptkbp:used_for |
preventing severe COVID-19
|
| gptkbp:bfsParent |
gptkb:Regeneron_Pharmaceuticals,_Inc.
|
| gptkbp:bfsLayer |
5
|